Regenxbio (RGNX) Capital Expenditures Growth (1y) (2016 - 2025)
Regenxbio (RGNX) Capital Expenditures Growth (1y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | 143.40% |
| 10 | Regenxbio | 506.45 Mn | 276.38 Mn | 21.22 Mn | 746.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 746.39% |
| Sep 30, 2025 | 72.37% |
| Jun 30, 2025 | -30.07% |
| Mar 31, 2025 | 83.84% |
| Dec 31, 2024 | 96.82% |
| Sep 30, 2024 | -87.84% |
| Jun 30, 2024 | 67.24% |
| Mar 31, 2024 | -88.44% |
| Dec 31, 2023 | -433.74% |
| Sep 30, 2023 | 366.18% |
| Jun 30, 2023 | 35.75% |
| Mar 31, 2023 | -56.07% |
| Dec 31, 2022 | 97.10% |
| Sep 30, 2022 | -96.36% |
| Jun 30, 2022 | -735.03% |
| Mar 31, 2022 | 189.44% |
| Dec 31, 2021 | -338.72% |
| Sep 30, 2021 | 827.81% |
| Jun 30, 2021 | -141.98% |
| Mar 31, 2021 | -18.16% |